Novo Nordisk H1 Net Profit Rises

Novo Nordisk reported strong first-half results, with net profit increasing to DKK 55.54 billion and sales growing 18% at constant exchange rates to DKK 154.9 billion, alongside a 29% CER rise in operating profit. However, the company lowered its 2025 sales growth forecast to 8-14% at CER and operating profit growth to 10-16% at CER, attributing the revised outlook to reduced growth expectations for the second half of 2025.

Analysis

Novo Nordisk reported a robust first half, with net profit increasing to 55.54 billion DKK from 45.46 billion DKK year-over-year, and earnings per share rising to 12.49 kroner from 10.17 kroner. The company's underlying operational strength was evident in its sales growth of 18% and operating profit growth of 29% at constant exchange rates (CER). However, this strong performance is contrasted by a more cautious forward outlook. Management has lowered its full-year 2025 guidance, now projecting sales growth of 8-14% at CER and operating profit growth of 10-16% at CER. This revision is directly attributed to anticipated lower growth in the second half of 2025, suggesting a potential peak in the current growth trajectory. Additionally, significant currency headwinds are expected to impact reported results, with sales and operating profit in Danish kroner projected to be 3 and 5 percentage points lower than CER figures, respectively.

Key Decisions for Investors

• Investors should weigh the company's strong first-half earnings against the newly lowered 2025 guidance, as the market is likely to focus on the future deceleration rather than past performance.
• It is crucial to monitor for further management commentary on the specific drivers behind the expected slowdown in the second half of 2025 to assess if this is a temporary issue or a new, lower growth trend.
• Factor in the stated currency headwinds, as the 3 to 5 percentage point drag on reported DKK sales and profit growth could materially impact financial models and final earnings per share.